Skip to content
Study details
Enrolling now

Phase 2 Trial of Tivozanib and Nivolumab for Kidney Cancer

M.D. Anderson Cancer Center
NCT IDNCT06053658ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

48

Study length

about 4.8 years

Ages

18+

Locations

5 sites in MA, MI, TX

What this study is about

This trial is testing if giving tivozanib with nivolumab can help control advanced kidney cancer. The treatment involves taking both medications.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Nivolumab
  • 2.Take Tivozanib

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVOral

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells), tivozanib

Drug routes

infusion, oral (Oral Capsule)

Endpoints

Primary: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Body systems

Oncology